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TO THE EDITOR
The involvement of the interferon
regulatory factor 4 gene (IRF4), also
known as multiple myeloma antigen 1
(MUM1), in balanced rearrangement or
translocation has been recently obser-
ved in a subset of cutaneous T-cell
lymphomas (CTCLs), such as cutaneous
anaplastic large-cell lymphoma (C-ALCL)
and transformed mycosis fungoides
(Feldman et al., 2009; Pham-Ledard
et al., 2009). IRF4 expression reaches a
high level in differentiated plasma cells
and is also detectable by immunostaining
in some activated T cells and melano-
cytes, with the latter providing internal
positive controls on skin sections (Falini
et al., 2000; Lu, 2008). Despite such a
restricted immunostaining pattern, IRF4
is an essential regulator at multiple steps
of B-cell differentiation, such as pre-B-
cell differentiation, germinal center for-
mation, immunoglobulin class switch
recombination, and terminal differentia-
tion of B cells to plasma cells, as shown
in IRF4-deficient mice (reviewed in
Shaffer et al., 2009). IRF4 is also essential
for T-helper (Th) cell differentiation and is
required for either Th2 or Th17 cell
development (Brustle et al., 2007; Zheng
et al., 2009). An oncogenic role of IRF4
has first been supported by the identifica-
tion of IRF4 involvement in the
t(6;14)(p25;q32) translocation in some
cases of multiple myeloma (MM) (Iida
et al., 1997). In t(6;14)(p25;q32), IRF4 is
juxtaposed with the immunoglobulin
heavy-chain gene locus leading to IRF4
deregulated expression (Iida et al., 1997;
Yoshida et al., 1999; Shaffer et al., 2008).
Alternatively, IRF4 rearrangements in
peripheral T-cell lymphoma do not
commonly involve either the TCRB or
the TCRA gene locus, as shown in eight
C-ALCL and two systemic T-cell lympho-
mas (Feldman et al., 2009).
Among primary cutaneous B-cell
lymphomas, primary cutaneous diffuse
large B-cell lymphoma, leg type
(PCLBCL, leg type) is an original entity
with poor prognosis that was first
reported in 1996 and that mostly affects
the leg(s) in elderly but may also arise at
other sites in approximately 10% of
cases (Vermeer et al., 1996; Willemze
et al., 2005; Meijer et al., 2008).
PCLBCL, leg type, differs from primary
cutaneous follicle center lymphoma by
the presence of confluent sheets of
centroblasts and immunoblasts, many
with a peculiar round cell morphology,
which strongly express B-cell CLL/
lymphoma 2 (BCL2), IRF4, and fork-
head box P1 (FOXP1) (Willemze et al.,
2005; Meijer et al., 2008). Interestingly,
round cell morphology, strong BCL2
Abbreviations: FISH, fluorescence in situ hybridization; IRF4, interferon regulatory factor 4; MM, multiple
myeloma; MUM1, multiple myeloma antigen 1; PCLBCL, leg type, primary cutaneous diffuse large B-cell
lymphoma, leg type
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expression (450% of cells), IRF4 ex-
pression (430% of cells), or FOXP1
expression have been used to differ-
entiate PCLBCL, leg type, from primary
cutaneous follicle center lymphoma
with a diffuse pattern, although 10%
of the latter may express BCL2, IRF4, or
less frequently FOXP1 (Kodama et al.,
2005; Senff et al., 2007). Strong BCL2
expression has been found in 85–100%
of PCLBCL, leg type, whereas IRF4
expression was found in 68–90% of
cases that may also depend on differ-
ences in fixation and antigen retrieval
procedures or positivity threshold
between series (Kodama et al., 2005;
Grange et al., 2007; Senff et al., 2007).
With some differences between series,
each of these histological criteria has
been reported as an independent
adverse prognostic factor together with
clinical parameters such as location on
the leg or multiple skin lesions (Kodama
et al., 2005; Grange et al., 2007; Senff
et al., 2007). Conversely, IRF4 expres-
sion is a rare finding in other primary
cutaneous B-cell lymphomas (Kodama
et al., 2005; Willemze et al., 2005;
Senff et al., 2007).
Owing to the oncogenic role of IRF4
translocation in MM and the detection
of IRF4 rearrangements in a subset
of CTCL with IRF4 expression (Pham-
Ledard et al., 2009), we decided
to analyze IRF4 expression and
rearrangements in 29 cases of PCLBCL,
leg type. Inclusion criteria were a
complete clinical staging and follow-
up to exclude lymphoma with second-
ary skin involvement. Formalin-fixed
paraffin-embedded sections were used
for immunostaining with an anti-MUM-
1 antibody and for fluorescence in situ
hybridization (FISH) analysis of IRF4
status with break-apart probes, as re-
ported recently (Pham-Ledard et al.,
2009). The 29 patients (mean age 82
years) had a male:female ratio of 10:19
and presented typical lesions of
PCLBCL, leg type, located on the leg
(n¼21), upper limb (n¼ 4), trunk
(n¼1), or head and neck (n¼ 3) (see
Supplementary Table S1 online). Immu-
nostaining was scored positive in 25 out
of 29 analyzed cases (86%) with
450% of tumor cells expressing IRF4
(Figure 1a,c). It was scored negative in 4
out of 29 cases (14%) with o30%
positive tumor cells. BCL2 immunos-
taining was scored positive in 26 out of
29 cases (90%) and negative in 3 out of
29 cases (10%) with no overlap with
negative IRF4 immunostaining. No case
showed a break-apart or split signal. A
normal FISH pattern with two fusion
signals was observed in 26 out of 29
cases (90%; Figure 1b). In two cases,
one extra copy of IRF4 locus with three
fusion signals was observed in 64
and 75% of tumor cells, respectively
(Figure 1d). A single case showed a
deletion of one IRF4 allele in 67% of
tumor cells (Figure 1f), although this
case showed a strong IRF4 immuno-
reactivity (Figure 1e).
Our study clearly shows that the
typical IRF4 expression by PCLBCL, leg
type, is not associated with IRF4 gene
rearrangement or amplification. More-
over, extra copy of IRF4 allele was not
associated with an increase in IRF4
immunostaining pattern, as previously
reported in CTCL (Pham-Ledard et al.,
2009). Alternatively, the four PCLBCL,
leg type, cases with negative IRF4
immunostaining showed a normal FISH
pattern and the single case with IRF4
monoallelic deletion was strongly IRF4
positive. Therefore, IRF4 expression in
PCLBCL, leg type, is likely to be the
result of several mechanisms, including
differentiation stage, epigenetic regula-
tion, or other oncogenes deregulation.
Recent data have shown that constitu-
tive activation of the intrinsic-mediated
apoptosis pathway with concomitant
downstream inhibition of this pathway
may support the cellular resistance of
PCLBCL, leg type, to chemotherapy
(van Galen et al., 2008). Moreover,
RNA interference with IRF4 expression
is lethal in MM cell lines, irrespective of
IRF4 genetic status (Shaffer et al., 2009).
Whether PCLBCL, leg type, is addicted
to the presence of IRF4 and dependent
Figure 1. Interferon regulatory factor 4 (IRF4) expression according to IRF4 fluorescence in situ hybridization (FISH) pattern in three cases of cutaneous large
B-cell lymphoma, leg type (scale bar¼5 lm). (a, b, left panel) Skin sections of first case. (a) IRF4 immunostaining in most tumor cells. (b) Normal two fusion
signals pattern showing IRF4 normal status. (c, d, middle panel) Skin sections of second case. (c) IRF4 immunostaining in approximately 50% of tumor cells.
(d) The three fusion signals pattern showing one extra copy of IRF4 locus. (e, f, right panel) Skin sections of the third case. (e) IRF4 immunostaining in
approximately 90% of tumor cells. (f) The one fusion signal pattern showing monoallelic deletion of IRF4 locus.
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upon its functions for tumor cell survi-
val or proliferation has to be further
analyzed.
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